Changeflow GovPing Government & Legislation National Health (Originator Brand) Determinatio...
Priority review Rule Added Final

National Health (Originator Brand) Determination 2025

Favicon for www.legislation.gov.au AU Federal Legislative Instruments (7-day)
Published
Detected
Email

Summary

The Australian Department of Health has issued the National Health (Originator Brand) Determination 2025 under the National Health Act 1953. The instrument defines what constitutes an 'originator brand' for the purposes of pharmaceutical regulation and Schedule 1 lists the specific originator brands. This determination affects how medicines are classified, priced, and substituted under Australia's pharmaceutical regulatory framework.

Published by DoH (AU) on legislation.gov.au . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The National Health (Originator Brand) Determination 2025 establishes the criteria and lists the brands that qualify as originator brands under the National Health Act 1953. Schedule 1 contains the enumerated originator brands. Section 6 provides the definitional framework for originator brand determination.

Pharmaceutical companies seeking originator brand status for their medicines will be directly affected, as this determination governs PBS pricing arrangements and whether generic substitution rules apply. Healthcare providers and dispensers should verify whether specific medicines are classified as originator brands, which affects prescription substitution practices. The instrument operates within the broader pharmaceutical pricing and reimbursement framework established by the National Health Act.

Archived snapshot

Apr 18, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

- Interactions

National Health (Originator Brand) Determination 2025

In force Administered by
- Department of Health, Disability and Ageing
This item is authorised by the following title:


View document Legislative instrument Filter active Table of contents
- 1 Name
- 4 Authority
- 5 Definitions
- 6 Originator Brand
- Schedule 1–Originator Brand
- Endnotes
- Endnote 1—About the endnotes
- Endnote 2—Abbreviation key
- Endnote 3—Legislation history
- Endnote 4—Amendment history

Named provisions

Originator Brand Definitions Schedule 1 – Originator Brand

Get daily alerts for AU Federal Legislative Instruments (7-day)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from DoH (AU).

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
DoH (AU)
Published
April 1st, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
F2026C00332

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug pricing Brand determination Pharmaceutical regulation
Geographic scope
Australia AU

Taxonomy

Primary area
Healthcare
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Intellectual Property

Get alerts for this source

We'll email you when AU Federal Legislative Instruments (7-day) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!